Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis AB's (publ) Chief Financial Officer (CFO) Johny Humaloja has resigned from his position to take on new challenges.

Johny has been employed by Genovis since 2019 and he will continue in his current role during the notice period. A process to recruit a new CFO will be initiated immediately.

"During his time at Genovis, Johny has contributed to the development of the Group's financial management. I would like to thank him for his contribution to Genovis and wish him good luck in his new endeavors," says Fredrik Olsson, CEO of Genovis

Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.